Oncolytics Biotech Inc T.ONC

Big Pharma will be seeking innovation to drive profits now

[Noteable]

April 08, 2022 -  US Congress Introduces Bills to Strengthen Pharma Competition, Promote Innovation

The first bill, "The Discounted Drugs for Clinical Trials Act," would amend the Federal Food, Drug, and Cosmetic Act in order to provide researchers access to drugs or biologics at a price that is no higher than the cost of manufacturing the product.

[ ONCY has the benefit of already providing researchers with access to pelareorep for investigator sponsored trials (IST) that have been and are presently being conducted - thus giving any acquirer of ONCY to claim ownership of this action under the bill.

Consequently, any acquirer of ONCY would have the advantage of establishing the cost of manufacturing of pelareorep by means of its own internal discretion, since the cost of manufacturing has not yet been fully determined or publically disclosed. ] 

The second bill .. The "Pharmaceutical Research and Transparency Act of 2022" is designed to amend the Public Health Service Act and the Security Exchange Act in order to increase transparency into the costs of clinical trials, which are not regularly disclosed by the industry. The bill would require drug companies to report disaggregated clinical trial costs in filings with the U.S. Securities Exchange Commission within one year of trial completion.

The legislation is expected to provide "valuable data on companies' investments in innovation and enable evaluation of pharmaceutical industry claims about R&D." The bill's impetus came from the three-year investigation that showeONCY's d companies "spend more to enrich shareholders and executives than they do on R&D."

[Once again any acquirer of ONY would have the benefit of access to ONCY's R&D clinical trial costs as an off-set to the requirements of Congress's second bill.

The ability to use ONCY's overall R&D costs would benefit any Big Pharma company who has generated significant revenue from overall annual sales, such as a pharma company like Pfizer which could apply these costs at year end against Pfizer's Covid-19 vaccine revenues for 2022.]

The third legislative bill, "The Generic Substitution Non-Interference Act," aims to block anticompetitive practices surrounding the "dispense as written" prescriptions for branded drugs, even when a generic is available.

[And again any acquirer of ONCY would have the benefit of the intravenous use of pelareorep to treat multiple cancers since the drug will only be delivered by oncologists in either a hospital or office setting in an acute setting and without presecription, AND ONCY's oncolytic virus pelareorep is a patent protected proprietary drug without any generic competition, and will remain that way until at least 2033 or longer due to patent protection and the FDA's 12 year marketing exclusivity on biologics granted through the BPCI Act of 2009.] 

https://www.biospace.com/article/congress-files-multiple-bills-to-curb-practices-of-limiting-competition-within-the-pharmaceutical-industry-/